Stian Foss
Overview
Explore the profile of Stian Foss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life
Mester S, Chan C, Lustig M, Foss S, Jansen J, Leangen Herigstad M, et al.
PNAS Nexus
. 2025 Mar;
4(2):pgaf042.
PMID: 40041621
Most therapeutic antibodies are based on immunoglobulin G (IgG) due to their potent effector functions and long plasma half-life. However, also monomeric IgA has emerged as an attractive candidate for...
2.
Foss S, Sakya S, Aguinagalde L, Lustig M, Shaughnessy J, Cruz A, et al.
Nat Commun
. 2024 Mar;
15(1):2007.
PMID: 38453922
Monoclonal IgG antibodies constitute the fastest growing class of therapeutics. Thus, there is an intense interest to design more potent antibody formats, where long plasma half-life is a commercially competitive...
3.
Jorstad O, Foss S, Gjolberg T, Mester S, Nyquist-Andersen M, Sivertsen M, et al.
Int J Retina Vitreous
. 2023 Nov;
9(1):65.
PMID: 37936232
Background: Intravitreal injection (IVI) of antibody biologics is a key treatment approach in ophthalmology. Pharmaceutical compounding and storage of prefilled syringes for IVI must take place without impairing the structure...
4.
Lustig M, Chan C, Jansen J, Brautigam M, Kolling M, Gehlert C, et al.
Front Immunol
. 2023 Jun;
14:1178817.
PMID: 37346044
Upregulation of surface expressed sialoglycans on tumor cells is one of the mechanisms which promote tumor growth and progression. Specifically, the interactions of sialic acids with sialic acid-binding immunoglobulin-like lectins...
5.
Gjolberg T, Wik J, Johannessen H, Kruger S, Bassi N, Christopoulos P, et al.
Nat Commun
. 2023 May;
14(1):3109.
PMID: 37253747
Antibody-based blocking of vascular endothelial growth factor (VEGF) reduces choroidal neovascularization (CNV) and retinal edema, rescuing vision in patients with neovascular age-related macular degeneration (nAMD). However, poor response and resistance...
6.
Mukadam A, Miller L, Smith A, Vaysburd M, Sakya S, Sanford S, et al.
Science
. 2023 Mar;
379(6639):1336-1341.
PMID: 36996217
Aggregates of the protein tau are proposed to drive pathogenesis in neurodegenerative diseases. Tau can be targeted by using passively transferred antibodies (Abs), but the mechanisms of Ab protection are...
7.
Gjolberg T, Frick R, Mester S, Foss S, Grevys A, Hoydahl L, et al.
Commun Biol
. 2022 Aug;
5(1):832.
PMID: 35982144
Antibody-based therapeutics (ABTs) are used to treat a range of diseases. Most ABTs are either full-length IgG1 antibodies or fusions between for instance antigen (Ag)-binding receptor domains and the IgG1...
8.
Zakrzewicz A, Wurth C, Beckert B, Feldhoff S, Vanderheyden K, Foss S, et al.
Cells
. 2022 May;
11(10).
PMID: 35626757
The authors wish to make the following changes to their paper [...].
9.
Foss S, Jonsson A, Bottermann M, Watkinson R, Lode H, McAdam M, et al.
Sci Immunol
. 2022 Apr;
7(70):eabj1640.
PMID: 35486676
Humans have four IgG antibody subclasses that selectively or differentially engage immune effector molecules to protect against infections. Although IgG1 has been studied in detail and is the subclass of...
10.
Zakrzewicz A, Wurth C, Beckert B, Feldhoff S, Vanderheyden K, Foss S, et al.
Cells
. 2022 Mar;
11(6).
PMID: 35326398
Pemphigus vulgaris is an autoimmune blistering disease of the epidermis, caused by autoantibodies against desmosomal proteins, mainly desmogleins 1 and 3, which induce an impairment of desmosomal adhesion and blister...